<DOC>
	<DOC>NCT02356328</DOC>
	<brief_summary>This observational study is intended to collect outcome data from a cohort of 30 patients suffering from dry eye disease due to chronic ocular Graft-versus-Host Disease (GvHD) who are treated with the medical device NovaTears® eye drops for a duration of 11 to 13 weeks.</brief_summary>
	<brief_title>NovaTears® Eye Drops Observational Study NT-003</brief_title>
	<detailed_description />
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>According to NovaTears® instruction for use ≥ 18 years Patients after an allogeneic hematopoietic stem cell transplantation with dry eye disease due to chronic ocular GraftversusHost Disease Ability and willingness to provide written Informed Consent Ability and willingness to participate in all examinations Willingness and ability to return for follow up visit Patients with known hypersensitivity to any of the components of NovaTears® Patients with contact lenses, pregnancies, or who are breast feeding Patients with dry eye disease caused by any other known underlying systemic disease Patients planning an ophthalmologic surgical procedure during the course of this PMCF study Patients using lipidcontaining or tearfilm stabilizing eye drops/sprays except cyclosporin formulations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>